Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody

Image: The dosing of the first patient in this Phase 1 trial triggers milestone payments of a total of €15m to OSE Immunotherapeutics from Boehringer Ingelheim. Photo: courtesy of Madras150.